NAVA Navamedic ASA
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases, fat metabolism, renal, nutritional support, and ketogenic diet. In addition, it provides consumer health products consisting of non-prescription drugs and health care products for erectile dysfunction, pain, gastro-related problems, and others primarily through pharmacies and drugstores; prescription medicines covering obesity, Parkinson's disease, urology, and cardiology; and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.…
Industry Peers
Medical DistributionKey Statistics
About Navamedic (OSL: NAVA)
›
Navamedic (OSL: NAVA) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Medical Distribution industry, part of the Healthcare sector, and reports about 38 employees.
The shares were at 10.35 NOK on 19 November 2026, down 51.9% over 52 weeks. Its 52-week range is 9.820 NOK to 26.50 NOK: the price is 60.9% below the high and 5.4% above the low.
Its market capitalisation is 248.21M NOK.
Navamedic reports return on equity of -7.0%, an operating margin of -0.2% and revenue down 13.2% year over year.
Its debt exceeds its cash by 134.25M NOK, a debt-to-equity ratio of 0.68. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 20.63 NOK is 99.4% above the current price. The next earnings report is expected on 12 February 2027.